Percentage Change in Mean Absorbed Dose per Response Category
| Level | PR | Stable disease | PR | CR* | P (trend) |
| Patient level without new lesions | n = 8 | n = 17 | n = 11 | n = 1 | |
| Unadjusted | Reference | 53.8 (5.6–24.2) | 74.6 (18.6–57.6) | — | 0.012 |
| Adjusted† | Reference | 62.0 (10.4–136.0) | 77.3 (18.3–163.6) | — | 0.019 |
| Patient level with new lesions‡ | n = 23 | n = 6 | n = 7 | n = 1 | |
| Unadjusted | Reference | 29.8 (−15.1–98.6) | 44.4 (1.4–106.0) | — | 0.041 |
| Adjusted† | Reference | 18.7 (−24.3–85.4) | 38.1 (−5.8–101.9) | — | 0.12 |
| Tumor level | n = 23 | n = 49 | n = 20 | n = 23 | |
| Unadjusted | Reference | 31.1 (−3.2–78.8) | 71.5 (17.1–150.4) | 95.2 (34.7–183.6) | 0.00030 |
| Adjusted | Reference | 35.2 (0.2–87.5) | 72.2 (16.6–151.3) | 94.8 (33.9–188.4) | 0.00068 |
↵* As there was only 1 patient with complete metabolic response, categories CR and PR were taken together at patient level.
↵† Analyses were adjusted for previous treatment and tumor load or tumor volume (tumor-level analyses).
↵‡ In which case patients were categorized as having PR.
Data are in grays, with 95% CIs in parentheses. For interpretation at tumor level, average dose is 95.23% higher in CR than PD (95% CI, 4.69%–183.62%).